PEG-MGF

The PEG-MGF evidence base cited here is 6 sources — 1 clinical, 4 preclinical, 1 review. Its strongest evidence is human — a clinical study, most recently 2016 ("Effects of resistance training on expression of IGF-I splice variants in…"). Regulatory status: Not FDA-approved.

• PEGylation of the MGF E-domain peptide extends its half-life by creating a hydrophilic polymer shield that reduces renal clearance and protease degradation, converting a peptide that degrades in minutes into one with a half-life measured in hours — enabling systemic rather than purely local delivery.
• A sheep model of myocardial infarction found that intravenous administration of the MGF E-domain reduced the area of compromised cardiac muscle by 35% compared to controls and preserved systolic function, suggesting that when delivered systemically at sufficient concentrations the peptide reaches ischemic tissue and is cardioprotective.
• Controlled sustained release of MGF from mesoporous silica scaffolds on titanium prosthetics promoted genuine muscle regeneration into the implant via Akt/mTOR signaling, underscoring the importance of delivery format (slow local release vs. rapid bolus) in translating MGF's bioactivity into functional tissue outcomes.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.